Accuray Incorporated · NASDAQ:ARAY
Accuray — Q3 FY2022 Earnings Presentation
13 slides from Accuray's earnings presentation, Apr 27, 2022
Slide 1: Q3'FY22 Earnings Call
Q3’FY22 Earnings Call April 27, 2022 Exhibit 99.3
Slide 2: Safe Harbor Statement
Proprietary and Confidential Property of Accuray Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securiti
Slide 3: Executive Summary Q3'FY22
Executive Summary Q3’FY22 Good business performance amid supply and logistic challenges Q3 ending backlog at $580M with 1% Q3 Y/Y order growth 2% net installed base growth Q3 Y/Y to drive future recurring service and upgrade revenues 12% YTD Q3 revenue growth Y/Y while continuing momentum with R&D i
Slide 4: Our Vision: To Expand the Curative Power of Radiation Therapy
Our Vision: To EXPAND the CURATIVE POWER of RADIATION THERAPY to improve as many lives as possible Broader treatment options Beyond oncology Global patient access Enable advanced treatments Survival, long term outcomes Quality of life Precision technology Superior patient experience Partnerships Foc
Slide 5: Strategy for Accelerating Momentum
Strategy for Accelerating Momentum Financial model designed to both invest as well as grow the top line Reposition for Success Enhanced leadership team Established China joint-venture Introduced artificial intelligence (AI)-driven Synchrony® technology Reset cost structure to increase operating leve
Slide 6: Accuray Systems: Differentiated Solutions
Accuray Systems: Differentiated Solutions TomoTherapy® System Radixact® System Personalized Universal Fast S7™ System CyberKnife® Tracking, Gating-free, ITV-free Precise Speed Treatment Planning System Accuray Precision® Efficient Integrated Automated Ultimate IMRT/SBRT Workhorse Connectivity to the
Slide 7: Gross Order Performance by Region in YTD Q3'FY22
AMS 57% YTD Q3 Y/Y1 EIMEA (10%) YTD Q3 Y/Y1 APAC 50% YTD Q3 Y/Y1 JAPAN 9% YTD Q3 Y/Y1 1 Percentages above are calculated using actual dollars for Orders. 2 MarketsAndMarkets RADIOTHERAPY MARKET - GLOBAL FORECAST 2021-2026 Gross Order Performance by Region in YTD Q3’FY22 Four (4) Accuray business reg
Slide 8: Q3'FY22 and YTD Q3'22 Financials
Q3’FY22 and YTD Q3’22 Financials Strong financial performance Gross orders $88.6M 1% $243.9M 14% Revenues $96.2M (6%) $319.9M 12% Product $43.2M (9%) $156.7M 30% Service $53.0M (4%) $163.2M (1%) Op. Expenses $35.1M - $110.8M 13% R&D $14.1M 6% $43.2M 16% SG&A $21.0M (4%) $67.6M 12% Adj. EBITDA 1 $5.4
Slide 9: In Summary
In Summary Year to date Momentum in Orders and Revenue Strongest Product Portfolio and Pipeline in Company’s History Multiple Growth Catalysts and Global Commercial Execution Strengthened Leadership Team and Operational Foundation Positioned for Accelerated Revenue Growth and Market Share Gains
Slide 10: Thank you
ACCURAY Thank you Proprietary and Confidential Property of Accuray
Slide 11: GAAP to Adjusted EBITDA Q3 FY2022 and Q3 FY2021 Actual
GAAP to Adjusted EBITDA Q3 FY2022 and Q3 FY2021 Actual Reconciliation of Net Income to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) $K GAAP net income Stock-based compensation Interest expense, net Provision for income taxes Adju
Slide 12: GAAP to Adjusted EBITDA YTD Q3 FY2022 and YTD Q3 FY2021 Actual
GAAP to Adjusted EBITDA YTD Q3 FY2022 and YTD Q3 FY2021 Actual Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) $K GAAP net income (loss) Stock-based compensation Interest expense, net Provision
Slide 13: GAAP to Adjusted EBITDA FY22 Guidance
GAAP to Adjusted EBITDA FY22 Guidance Guidance Reconciliation of Net loss to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) $K GAAP net loss Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA